Naxitamab Naxitamab-gqgk; Humanized 3F8; Hu3F8|cas:1879925-92-4|西域试剂

Naxitamab Naxitamab-gqgk; Humanized 3F8; Hu3F8,98.13%

产品编号：Bellancom-P99206| CAS NO：1879925-92-4

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99206	￥2300.00	杭州北京（现货）
Bellancom-P99206	￥5750.00	杭州北京（现货）
Bellancom-P99206	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Naxitamab Naxitamab-gqgk; Humanized 3F8; Hu3F8

产品介绍

Naxitamab (Hu3F8) 是一种人源化单克隆抗体，靶向二氮冈糖苷 GD2 (hu3F8)。Naxitamab 可用于神经母细胞瘤、骨肉瘤和其他 GD2 阳性癌症的研究。

生物活性

Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers.

体外研究

Naxitamab (Hu3F8; 72 h) has cytotoxicity against neuroblastoma cell line LAN-1 with an EC₅₀ value of 5.1 μg/mL.
Naxitamab (0.1-1 μg/mL; 4 h; peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) has antibody-dependent cell-mediated cytotoxic effects (ADCC).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Naxitamab (Hu3F8; 100 mg/kg; i.v.; twice a week, for 4 weeks; athymic nude mice with LAN-1 xenografts) inhibits tumor growth in neuroblastoma xenografts.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female athymic nude mice with LAN-1 xenografts
Dosage:	100 mg/kg
Administration:	Intravenous injection; twice a week, for 4 weeks
Result:	Inhibited tumor growth and prolonged the survival time.

体内研究

Naxitamab (Hu3F8; 100 mg/kg; i.v.; twice a week, for 4 weeks; athymic nude mice with LAN-1 xenografts) inhibits tumor growth in neuroblastoma xenografts.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female athymic nude mice with LAN-1 xenografts
Dosage:	100 mg/kg
Administration:	Intravenous injection; twice a week, for 4 weeks
Result:	Inhibited tumor growth and prolonged the survival time.